7. INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2017

Intangible Assets

7. INTANGIBLE ASSETS

Intangible assets at September 30, 2017 and December 31, 2016 consist of the following:

	September 30, 2017						December 31, 2016
	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
Trademark and other intangible rights related to Nabi-HB®	$	4,100,046	$	185,478	$	3,914,568	$	—	$	—	$	—
Right to intermediates		907,421		41,050		866,371		—		—		—
Customer contract		1,076,557		120,321		956,236		—		—		—
Total	$	6,084,024	$	346,849	$	5,737,175	$	—	$	—	$	—

Under the previous contract manufacturing agreement between ADMA and BPC, intermediate by-products derived from the manufacture of RI-002 were property of Biotest. As a result of the transaction, ADMA now has the right to these intermediate products. The customer contract pertains to a contract manufacturing agreement with a third party that the Company assumed upon the completion of the acquisition of the Biotest Assets. Amortization expense related to these acquisition-related intangible assets for the three and nine months ended September 30, 2017 was $0.3 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:

Remainder of 2017	$	273,828
2018		1,095,314
2019		1,095,314
2020		816,675
2021		715,352